Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41401-020-00554-8 http://scihub22266oqcxt.onion/10.1038/s41401-020-00554-8 33110240!7588589!33110240     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33110240&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Acta+Pharmacol+Sin 2020 ; 41 (12): 1539-1546 Nephropedia Template TP {{tp|p=33110240|t=2020. Hypoxia, HIF-1alpha, and COVID-19: from pathogenic factors to potential therapeutic targets |pdf=|usr=}}{{33110240}} gab.com Text Hypoxia, HIF-1alpha, and COVID-19: from pathogenic factors to potential therapeutic targets JO: Acta Pharmacol Sin http://www.kidney.de/pget.php?&tw=1&pmid=33110240 #FOAvip The pandemic of coronavirus disease 2019 (COVID-19) and its pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have become the greatest current threat to global public health. The highly infectious SARS-CoV-2 virus primarily attacks pulmonary tissues and impairs gas exchange leading to acute respiratory distress syndrome (ARDS) and systemic hypoxia. The current pharmacotherapies for COVID-19 largely rely on supportive and anti-thrombi treatment and the repurposing of antimalarial and antiviral drugs such as hydroxychloroquine and remdesivir. For a better mechanistic understanding of COVID-19, our present review focuses on its primary pathophysiologic features: hypoxia and cytokine storm, which are a prelude to multiple organ failure and lethality. We discussed a possible link between the activation of hypoxia inducible factor 1alpha (HIF-1alpha) and cell entry of SARS-CoV-2, since HIF-1alpha is shown to suppress the angiotensin-converting enzyme 2 (ACE2) receptor and transmembrane protease serine 2 (TMPRSS2) and upregulate disintegrin and metalloproteinase domain-containing protein 17 (ADAM17). In addition, the protein targets of HIF-1alpha are involved with the activation of pro-inflammatory cytokine expression and the subsequent inflammatory process. Furthermore, we hypothesized a potential utility of so-called "hypoxic conditioning" to activate HIF-1alpha-induced cytoprotective signaling for reduction of illness severity and improvement of vital organ function in patients with COVID-19. Taken together, we would propose further investigations into the hypoxia-related molecular mechanisms, from which novel targeted therapies can be developed for the improved management of COVID-19. Twit Text FOAVip Hypoxia, HIF-1alpha, and COVID-19: from pathogenic factors to potential therapeutic targets ????Acta Pharmacol Sin http://www.kidney.de/pget.php?&tw=1&pmid=33110240 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33110240 #FOAvip English Wikipedia <ref>{{Cite pmid|33110240}}</ref> Hypoxia, HIF-1alpha, and COVID-19: from pathogenic factors to potential therapeutic targets #MMPMID33110240 Serebrovska ZO; Chong EY; Serebrovska TV; Tumanovska LV; Xi L Acta Pharmacol Sin 2020[Dec]; 41 (12): 1539-1546 PMID33110240show ga The pandemic of coronavirus disease 2019 (COVID-19) and its pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have become the greatest current threat to global public health. The highly infectious SARS-CoV-2 virus primarily attacks pulmonary tissues and impairs gas exchange leading to acute respiratory distress syndrome (ARDS) and systemic hypoxia. The current pharmacotherapies for COVID-19 largely rely on supportive and anti-thrombi treatment and the repurposing of antimalarial and antiviral drugs such as hydroxychloroquine and remdesivir. For a better mechanistic understanding of COVID-19, our present review focuses on its primary pathophysiologic features: hypoxia and cytokine storm, which are a prelude to multiple organ failure and lethality. We discussed a possible link between the activation of hypoxia inducible factor 1alpha (HIF-1alpha) and cell entry of SARS-CoV-2, since HIF-1alpha is shown to suppress the angiotensin-converting enzyme 2 (ACE2) receptor and transmembrane protease serine 2 (TMPRSS2) and upregulate disintegrin and metalloproteinase domain-containing protein 17 (ADAM17). In addition, the protein targets of HIF-1alpha are involved with the activation of pro-inflammatory cytokine expression and the subsequent inflammatory process. Furthermore, we hypothesized a potential utility of so-called "hypoxic conditioning" to activate HIF-1alpha-induced cytoprotective signaling for reduction of illness severity and improvement of vital organ function in patients with COVID-19. Taken together, we would propose further investigations into the hypoxia-related molecular mechanisms, from which novel targeted therapies can be developed for the improved management of COVID-19. |*COVID-19 Drug Treatment[MESH] |Animals[MESH] |Antiviral Agents/*pharmacology[MESH] |COVID-19/physiopathology/virology[MESH] |Cytokine Release Syndrome/virology[MESH] |Drug Development[MESH] |Drug Repositioning[MESH] |Humans[MESH] |Hypoxia-Inducible Factor 1, alpha Subunit/metabolism[MESH] |Hypoxia/drug therapy/virology[MESH] |Molecular Targeted Therapy[MESH]Hypoxia, HIF-1alpha, and COVID-19: from pathogenic factors to potentia(epmc).pdf DeepDyve Pubget Overpricing